Need professional-grade analysis? Visit stockanalysis.com
$163.57M
N/A
N/A
N/A
Pacific Edge Ltd (PEB) trades on Australian Securities Exchange in AUD. The company is classified in the Healthcare sector under the Diagnostics & Research industry. The stock currently trades at AUD0.15.
Over the past year, PEB has traded between a low of AUD0.07 and a high of AUD0.22. The stock has gained 36.4% over this period. It is currently 31.8% below its 52-week high.
Pacific Edge Ltd has a market capitalization of $163.57M.
Pacific Edge Limited, a cancer diagnostics company, engages in development and commercialization of bladder cancer diagnostic and prognostic tests for patients. It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the detection and surveillance of bladder cancer. It also develops Cxbladder Triage, a frontline diagnostic product that helps de-intensify clinical work-up for patients with haematuria who have a low probability of bladder cancer; and Cxbladder Monitor, a non-invasive surveillance alternative that reduces the burden of repeated cystoscopy in patients with a low risk of recurrence. In addition, the company is developing products for bladder, gastric, colorectal, endometrial cancers, and melanoma. Pacific Edge Limited was incorporated in 2001 and is headquartered in Dunedin, New Zealand.
Side-by-side comparison against top Healthcare peers.